The Latest Breaking News from Novartis

Novartis is betting big on radioligand cancer therapy, but while the long-term growth story looks strong, NVS stock may face a short-term pullback

Tourmaline Bio, Inc. (NASDAQ:TRML) shares surged Tuesday after Novartis AG (NYSE:NVS) announced a $1.4 billion acquisition of the U.S.-based biotech, strengthening the Swiss drugmaker’s pipeline of cardiovascular and kidney treatments.

Novartis AG (NYSE:NVS) released topline results on Tuesday from the VAYHIT2 Phase 3 trial evaluating ianalumab plus eltrombopag in patients with primary immune thrombocytopenia (ITP) previously treated with corticosteroids.

Novartis AG (NYSE:NVS) on Monday released topline data from two Phase 3 trials, NEPTUNUS-1 and NEPTUNUS-2, evaluating ianalumab (VAY736) in adults with active Sjögren’s disease.

U.S. trade partners are reacting to President Donald Trump’s executive order that would introduce new tariffs on many of them in seven days

The first malaria treatment for babies and very young children of 2 months up to 5 years was approved for use by Swiss agency for therapeutic products, Swissmedic, in early July 2025. Until now, babies and very young children have been treated with medicines formulated for older children.

Editor’s Note: The title of the story has been corrected to reflect that the outlook was raised, instead of the erroneous “outlook cut” mentioned in the original title.

IN FULL

The newly approved medication is a lower-dose version of a tablet previously approved for other age groups